FDA OKs Merck tablet to reduce grass allergies

April 15, 2014 by The Associated Press

Merck & Co. says the Food and Drug Administration has approved its new tablet for grass allergies, Grastek, for patients five to 65 years old.

Meant as an alternative to weekly allergy shots, the tablet dissolves under the tongue. Taken daily for a few years, it gradually reduces sensitivity to common grasses, instead of temporarily relieving symptoms including sneezing, runny nose, and itchy, watery eyes.

Merck, based in Whitehouse Station, N.J., will market the in North America. Its partner, ALK-Abello, sells it in Europe as Grazas.

Merck said Grastek will be available in U.S. pharmacies in late April. However, it's best to start taking it three months before grass pollen season begins.

The drug can cause severe allergic reactions and shouldn't be used by patients with severe asthma.

Explore further: Merck: FDA reviewing tablet to eliminate allergy

Related Stories

Merck: FDA reviewing tablet to eliminate allergy

March 27, 2013

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that gradually reduces allergy symptoms over time, rather than just temporarily relieving ...

Merck says FDA reviewing its ragweed allergy therapy

May 8, 2013

Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...

So long snow, hello pollen

April 6, 2014

(HealthDay)—Although it still feels like winter in many parts of the United States, it's time to prepare for spring allergies, an expert says.

Recommended for you

Team finds early inflammatory response paralyzes T cells

August 18, 2015

In a discovery that is likely to rewrite immunology text books, researchers at UC Davis have found that early exposure to inflammatory cytokines, such as interleukin 2, can "paralyze" CD4 T cells, immune components that help ...

SIV shrugs off antibodies in vaccinated monkeys

August 11, 2015

New research on monkeys vaccinated against HIV's relative SIV calls into question an idea that has driven AIDS vaccine work for years. The assumption: a protective vaccine only needs to stimulate moderate levels of antibodies ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.